One of the earliest orally active GH secretagogues explored in development.
Also known as: NN703 · ghrelin receptor agonist
Part of the Growth hormone & IGF peptides cluster
Overview
Tabimorelin (NN703) is a potent, orally active agonist of the ghrelin/growth hormone secretagogue receptor and one of the earliest GH secretagogues developed. It remained an experimental compound, was never approved, and is not authorized by Health Canada. This page is educational and is not medical advice.
Source & context
Biological / chemical source: Synthetic orally active peptidomimetic
Primary research or clinical context: Experimental oral GH secretagogue; never approved and not authorized by Health Canada
Early secretagogue development
Tabimorelin helped establish that small orally active molecules could stimulate the growth hormone secretagogue receptor. It raised GH and IGF-1 levels, but clinical benefit in adults proved limited and development did not advance to approval.
Drug-interaction lesson
Tabimorelin was found to inhibit the CYP3A4 enzyme, highlighting a practical concern in secretagogue development: an oral compound must be evaluated for drug-metabolism interactions, not just receptor activity.
FAQ about Tabimorelin
What is Tabimorelin?+
Tabimorelin (NN703) is a potent, orally active agonist of the ghrelin/growth hormone secretagogue receptor and one of the earliest GH secretagogues developed. It remained an experimental compound, was never approved, and is not authorized by Health Canada. This page is educational and is not medical advice.
Is Tabimorelin an approved medicine?+
Tabimorelin is discussed here as a research / educational topic. Experimental oral GH secretagogue; never approved and not authorized by Health Canada. This is not medical advice.
What is the typical length of Tabimorelin?+
Tabimorelin is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.